SUO Annual Meeting at the AUA
Saturday, May 8, 2004
9:30 a.m. - 12:00 p.m.
Palace Hotel – Gold Ballroom
San Francisco, California

Translational Research: From Bench-to-Bedside and Beyond

9:30 a.m. - 9:40 a.m.
Introduction – Martin Gleave, MD

9:40 a.m. - 10:15 a.m.
Update on Targeted Therapeutics – Proof-of-Principle, Trial Design
9:40 a.m. - 9:47 a.m.
Rationale and Approach for CCI-779, an Inhibitor of mTOR, in Prostate Cancer – Robert Reiter, MD
9:47 a.m. - 9:54 a.m.
Rationale and Phase I Presurgery Trial Results for OGX-011, an Inhibitor of Clusterin, in Prostate Cancer – Kim Chi, MD
9:54 a.m. - 10:01 a.m.
Rationale and Approach for Geldanamycin, an Inhibitor of Hsp90, in Prostate Cancer – Howard I. Scher, MD
10:01 a.m. - 10:08 a.m.
Phase II Trial of Bevusumab (Avastin), an Inhibitor of VEGF, in Renal Cell Carcinoma – W. Marston Linehan, MD
10:08 a.m. - 10:15 a.m.
Patient Enrichment in GU Cancer Trials: Why and How? – Arie S. Beldegrun, MD

10:15 a.m. - 11:00 a.m.
Panel Discussion: Clinical Trial Issues in Drug Development
Moderator: Howard I. Scher, MD (Kim Chi, MD, Arie S. Beldegrun, MD, Robert Reiter, MD, W. Marston Linehan, MD, Joel Nelson, MD, Tony Tolcher, Tomasz Beer, MD)
- Clinical POP
- patient selection; enriching for optimal biochemical attributes
- surrogate endpoints
- commercialization issues

11:00 a.m. - 12:00 p.m.
Business Meeting

12:00 p.m. - 1:00 p.m.
Lunch
SUO Consensus Statement on Hormone-Refractory Prostate Cancer
Discussion

1:00 p.m. - 4:00 p.m.
OPEN SESSION
Location: Grand Ballroom

6:30 p.m. - 10:00 p.m.
SUO Member Banquet
Location: Camelot Room, Bank of America World Headquarters Building

Sponsored by the American Urological Association

Accreditation Statement:
The American Urological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association takes responsibility for the content, quality, and scientific integrity of this CME activity. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Policies.

Credit Hours Designation Statement:
The American Urological Association designates this educational activity for a maximum of 4.0 hours category I credit toward the American Medical Association's Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

AUA Policy on Disclosure:
As a sponsor accredited by the ACCME, the American Urological Association must ensure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a CME accredited sponsored program are expected to disclose to the audience any significant financial interest or other relationships with commercial supporters. The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine of the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. When unlabeled uses are discussed, these are also indicated.

The opinions and recommendations expressed by faculty/authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association.

Unlabeled or Unapproved Use of Drugs or Devices:
In accordance with the Essential Areas and Policies relating to commercial support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.